



FOR IMMEDIATE RELEASE

For Further Information:

Rick Carlson
Chief Executive Officer
(952) 476-9093
rcarlson@prourocare.com

Steven Hooser
Halliburton Investor Relations
(972) 458-8000
shooser@halliburtonir.com

ProUroCare Medical Inc. Announces Closing of Public Equity Offering

GOLDEN VALLEY, MN, January 13, 2009 – ProUroCare Medical Inc. (OTCBB:PUMD) announces the closing of its public offering of 3,050,000 units at \$1.00 per unit (before the underwriting discount). Each unit sold consists of one share of common stock and one redeemable warrant to purchase one share of common stock at an exercise price of \$1.30 per share. The Company intends to use the net proceeds of this offering to fund certain operating expenses and development costs as it pursues FDA 510(k) clearance of its ProUroScan™ prostate imaging system and to retire certain short-term liabilities.

The offering was underwritten by Feltl and Company, Inc., which has a 45-day option to purchase up to an additional 457,500 units to cover over-allotments, if any.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock or any other securities, nor will there be any sale of the shares of common stock or any other securities in any state of jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus forming a part of the effective registration statement.

Copies of the final prospectus relating to the offering may be obtained from Feltl and Company, Inc., 225 South Sixth Street, Suite 4200, Minneapolis, MN 55402.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a development stage company engaged in the business of developing for market innovative products for the detection and characterization of male urological prostate disease. The Company's primary focus is currently the ProUroScan prostate imaging system, which is now in clinical trials.